Biotech News

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Shattuck Labs (STTK)Shattuck LabsCompany update

AUSTIN, Texas and DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on November 10, 2026 (the “Grant Date”) to two newly-hired non-executive employees.

Related news

Shattuck Labs

Immune-Mediated Diseases Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells. SL-325 SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and...

Recent company news

Stock data

Close
4.55 USD
Market cap
373.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States